Scope and Claims Analysis for US Patent 10,940,124: Bupropion Plus Dextromethorphan Regimen for Major Depressive Disorder
What is US 10,940,124 claiming in plain scope terms?
US 10,940,124 claims a method of treating major depressive disorder (MDD) using a specific bupropion plus dextromethorphan regimen and specific patient stratification and outcome comparisons versus bupropion alone (and, in dependent claims, versus dextromethorphan alone and placebo).
The independent claim is claim 1. It requires all of the following elements:
Core combination and dose schedule (hard limits)
- Bupropion: about 105 mg bupropion hydrochloride (or molar equivalent free base or another salt)
- Dosing pattern:
- Once daily for the first three days
- Twice daily thereafter for at least 11 days
- Dextromethorphan: about 45 mg dextromethorphan hydrobromide (or molar equivalent free base or another salt)
- Dosing pattern:
- Once daily for the first three days
- Twice daily thereafter for at least 11 days
Patient selection criterion (hard limits)
- The human is selected for having a Clinical Global Impression-Severity (CGI-S) score of at least about 4.
Efficacy comparison requirement (hard limits)
- The patient must experience a greater reduction in MADRS after receiving the drug combination than what the patient would experience from receiving the same amount of bupropion alone.
So the claim is not just “use bupropion and dextromethorphan.” It is a treatment method with a specified titration/maintenance schedule, specific salts/dose magnitudes, patient severity gating, and a superiority requirement against bupropion alone.
How broad or narrow is the independent claim (claim 1)?
Claim 1 is moderately narrow on regimen and endpoints and broad on salt form and formulation modality, subject to the numeric constraints.
What broadens scope
- Salt equivalents are allowed:
- “about 105 mg of bupropion hydrochloride” can be met by molar equivalents using free base or “another salt form.”
- Likewise for dextromethorphan hydrobromide with “molar equivalent” alternatives.
What narrows scope
- Dose and titration cadence
- The “105 mg” and “45 mg” magnitudes plus:
- once daily for 3 days, then twice daily for at least 11 days
- Minimum comparative-efficacy concept
- The combination must outperform bupropion alone at the same bupropion amount, measured via greater reduction in MADRS
- Patient severity gate
- CGI-S must be at least about 4
Practical implication for freedom-to-operate
- Competitors aiming at a bupropion + dextromethorphan strategy will need to match (or escape) all three of:
1) the regimen pattern (3-day once daily then at least 11 days twice daily),
2) the dose targets (105 mg bupropion HCl and 45 mg dextromethorphan hydrobromide, or equivalents),
3) and the CGI-S selection with MADRS comparative superiority.
What do the dependent claims add (claims 2–20)?
Claims 2–20 tighten scope along three axes: comparators, specific dosing instantiation, and formulation/pharmacokinetic and timing surrogates.
Comparator narrowing
- Claim 2: combination is more effective than dextromethorphan alone (at the same amount of dextromethorphan).
- Claim 4: combination is more effective than bupropion alone specifically administered as in the regimen (105 mg once daily for 3 days then twice daily for at least 11 days).
Explicit dosing instantiation
- Claim 3: locks to the combination dosing at about 105 mg bupropion HCl + about 45 mg dextromethorphan hydrobromide with the same schedule, “once daily for first 3 days and twice daily thereafter for at least 11 days.”
Formulation modality
- Claim 5: dextromethorphan is immediate release.
- Claim 6: bupropion is sustained release.
- Claim 7: oral administration.
- Claims 8–9: both components in solid dosage forms.
Delivery configuration
- Claim 14: both drugs in a single dosage form.
- Claim 15: drugs in separate dosage forms.
Pharmacokinetic gating (biomarker constraints)
- Claim 10: bupropion Cavg ≥ about 10 ng/mL after dosing.
- Claim 11: bupropion Cmax ≥ about 90 ng/mL after dosing.
Disease severity
- Claim 12: moderate MDD.
- Claim 13: severe MDD.
Outcome magnitude and timing (MADRS thresholds)
- Claim 16: at least 10% reduction in MADRS vs baseline.
- Claim 17: at least 10% greater reduction in MADRS vs placebo.
- Claim 18: at least 10% greater reduction vs placebo within 2 weeks of first dosing.
- Claim 19: treatment effect assessed within 2 weeks.
- Claim 20: treatment effect assessed within 1 week.
Where is the “real claim leverage”? The scoring rules and comparisons
Claim 1’s novelty pressure comes from the superiority framing and the specific dosing pattern.
Comparison structure in claim 1
- The combination must produce a greater reduction in MADRS than bupropion alone at the same bupropion amount.
This is a counterfactual comparison embedded in the claim. In enforcement terms, that means the patentee’s proof model is likely built around clinical study arms or a validated statistical approach that reproduces “what would have happened” under bupropion-alone at the same dose.
Dependent comparator expansion
- Claim 2 adds a separate superiority requirement vs dextromethorphan alone.
- Claim 17–18 add superiority vs placebo with a 10% threshold and time anchor (2 weeks).
What is the implied treatment regimen template (operational takeaways)?
From claims 1 and 3, the regimen can be expressed as:
| Parameter |
Requirement in claim(s) |
| Bupropion active |
About 105 mg bupropion HCl (or molar equivalent salt/free base) |
| Dextromethorphan active |
About 45 mg dextromethorphan hydrobromide (or molar equivalent salt/free base) |
| Days 1–3 |
Once daily dosing for both components |
| Day 4 onward |
Twice daily dosing for at least 11 days |
| Minimum total exposed period |
At least 14 days (3 days once daily + at least 11 days twice daily) |
| Patient selection |
CGI-S ≥ about 4 |
| Endpoint |
MADRS reduction; combination must be greater than bupropion-alone at same bupropion amount |
The dependent claims further constrain the template with formulation and PK conditions.
How could a design-around work under the claim text (scope edges)?
This is a claim-text-driven map of possible “escape hatches” grounded in what the claims expressly require.
Regimen/dose-based edges
- Changing the titration pattern away from “once daily for first three days then twice daily for at least 11 days” is the most direct route to avoid claim 1.
- Moving materially away from the about 105 mg bupropion HCl and about 45 mg dextromethorphan hydrobromide targets (or preventing equivalence by salt selection) also impacts claim 1.
Patient-selection edge
- If patient inclusion does not use CGI-S ≥ 4 as the selection criterion, the method may fall outside claim 1’s explicit selection requirement.
Endpoint/comparison edge
- Claim 1 is written as a comparative “greater reduction” requirement versus bupropion alone.
- A program that demonstrates efficacy without meeting the claim’s comparative structure (for example, if bupropion-alone isn’t comparable “same amount” or the proof model does not establish “greater reduction in MADRS”) is outside the claim as written.
Dependent claim-specific edges
- Avoiding dependent constraints is possible by changing:
- release form (claim 5),
- sustained release requirement (claim 6),
- solid dosage form (claims 8–9),
- configuration (single vs separate) (claims 14–15),
- PK targets (claims 10–11),
- disease severity subset framing (claims 12–13),
- MADRS thresholds and timing windows (claims 16–20).
This matters because a competitor might still litigate against claim 1, but dependent claims can dictate settlement leverage if the competitor aligns with claim 1 while missing one or more dependent features.
Patent landscape: how US 10,940,124 typically positions against the bupropion/dextromethorphan depression space
You provided only the claims text and asked for scope and landscape for US Drug Patent 10,940,124. A landscape requires bibliographic facts (assignee, priority, related applications, cited prior art, claim construction history, and maintenance status). Without those, a complete, accurate landscape cannot be produced.
Given that constraint, the landscape section below is limited to claim-anchored structure rather than a bibliographic map.
Landscape by “claim family problem statement” (what the patent is trying to own)
US 10,940,124 is structured to own a specific slice of the depression combination space:
- Drug pair: bupropion + dextromethorphan
- Exact dose magnitudes: ~105 mg bupropion HCl and ~45 mg dextromethorphan HBr
- Titration/maintenance: once daily first 3 days, then twice daily for at least 11 days
- Severity gating: CGI-S ≥ 4
- Measured superiority: MADRS reduction outperforming bupropion alone (with dependent arms covering additional comparisons to dextromethorphan alone and placebo)
- Optional “upgrade” features: immediate release dextromethorphan, sustained release bupropion, solid oral dosing, specific PK targets, and timing/percentage MADRS thresholds
What that implies for competitors and investors
- Any new product attempting to compete in this pocket is likely to need:
- clinically supported superiority endpoints in the same comparative structure, and
- a regimen that matches the titration cadence, and
- patient selection aligned to CGI-S, and
- potentially PK alignment if dependent claims become central in a dispute.
Key claim matrix (what each claim locks)
| Claim |
Adds lock vs claim 1 |
| 1 |
Core regimen + CGI-S ≥ 4 + MADRS superiority vs bupropion alone |
| 2 |
Superiority vs dextromethorphan alone |
| 3 |
Explicit 105 mg bupropion HCl + 45 mg dextromethorphan HBr dosing with schedule |
| 4 |
Superiority vs bupropion-alone given exactly per the regimen |
| 5 |
Dextromethorphan immediate release |
| 6 |
Bupropion sustained release |
| 7 |
Oral administration |
| 8 |
Bupropion solid dosage form |
| 9 |
Dextromethorphan solid dosage form |
| 10 |
Bupropion Cavg ≥ ~10 ng/mL |
| 11 |
Bupropion Cmax ≥ ~90 ng/mL |
| 12 |
Moderate MDD subset |
| 13 |
Severe MDD subset |
| 14 |
Single dosage form for both actives |
| 15 |
Separate dosage forms |
| 16 |
≥10% MADRS reduction vs baseline |
| 17 |
≥10% greater MADRS reduction vs placebo |
| 18 |
≥10% greater vs placebo within 2 weeks |
| 19 |
Effect assessed within 2 weeks |
| 20 |
Effect assessed within 1 week |
Key Takeaways
- Claim 1 is not generic combination therapy; it is a specific regimen (105 mg bupropion HCl + 45 mg dextromethorphan hydrobromide) with a defined once daily for 3 days then twice daily for at least 11 days schedule plus CGI-S ≥ about 4 and a MADRS superiority comparison to bupropion alone.
- Dependent claims add tighter constraints on comparators (dextromethorphan alone, placebo), formulation (immediate vs sustained release, solid oral), delivery format (single vs separate), PK thresholds (bupropion Cavg/Cmax), severity subsets, and MADRS magnitude and timing (10% thresholds and assessment windows).
- For R&D or investment diligence, the enforcement-critical features are likely the regimen cadence, dose targets (with salt equivalents), CGI-S selection, and the comparative MADRS superiority framework.
FAQs
1) Does claim 1 require a specific formulation technology (e.g., XR/IR)?
No. Claim 1 specifies dose, schedule, CGI-S selection, and comparative MADRS superiority. Release form and sustained/immediate release appear in dependent claims (claims 5 and 6).
2) Can the claim be met with different salts?
Yes. Claim 1 allows molar equivalents for bupropion and dextromethorphan salts or free base forms, tied to the about 105 mg and about 45 mg anchors.
3) What is the earliest clinical timing mentioned in the claims?
Claims 19 and 20 require assessment within 2 weeks and within 1 week, respectively, and claims 17–18 include a 2-week comparator window for placebo superiority.
4) Is CGI-S only relevant for patient selection or also for outcomes?
It is used as a selection criterion in claim 1: the human is selected for having a CGI-S score at least about 4.
5) What single feature most strongly narrows claim 1 against generic “combination” use?
The combination must produce a greater MADRS reduction than bupropion alone at the same bupropion amount, combined with the specific once daily then twice daily schedule and dose targets.
References
- US Patent 10,940,124, claims 1–20 (text provided in prompt).
